FDA Action Alert: ChemoCentryx, Chimerix and AstraZeneca/FibroGen ANCA Vasculitis, Anemia, Arthritis Advisory Committee, Chronic Kidney Disease, Clinical Trials, FDA, New Drug Application (NDA), Prescription Drug User-Fee Act (PDUFA), R&D, Smallpox, Systemic Diseases After the July 4 holiday, the U.S. Food and Drug Administration has several items on the regulatory agency’s immediate calendar, including a couple target action dates and an advisory committee hearing. Read more July 6, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/05/FDA-Cites-Concerns-Over-ChemoCentryx’s-Avacopan-Trial-Data-Sending-Stock-off-a-Cliff-BioSpace-5-5-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-07-06 12:08:302021-07-06 12:57:32FDA Action Alert: ChemoCentryx, Chimerix and AstraZeneca/FibroGen